
自引率: 5.1%
被引量: 8640
通过率: 暂无数据
审稿周期: 1.6
版面费用: 暂无数据
国人发稿量: 92
投稿须知/期刊简介:
Leukemia and Lymphoma is an international journal that brings together clinical and laboratory data on lymphomas, leukemias and allied disorders including myeloma and myelodysplastic syndromes. Leukemia and Lymphoma publishes full-length papers, communications and reviews on clinical and therapeutic practice, laboratory diagnosis, pathology, cytology, ultrastructure, cytogenetics and cellular and molecular immunology; the journal aims at a strong clinical-pathologic correlation. Interesting or unusual case reports of importance are also included. In addition, an update is provided on the basic issues and advances in molecular genetics as applied to this field. The journal will provide an important reference source for physicians and scientists who deal essentially with the clinical and laboratory diagnosis, clinical care and therapy of patients with these disorders.
期刊描述简介:
Leukemia and Lymphoma is an international journal that brings together clinical and laboratory data on lymphomas, leukemias and allied disorders including myeloma and myelodysplastic syndromes. Leukemia and Lymphoma publishes full-length papers, communications and reviews on clinical and therapeutic practice, laboratory diagnosis, pathology, cytology, ultrastructure, cytogenetics and cellular and molecular immunology; the journal aims at a strong clinical-pathologic correlation. Interesting or unusual case reports of importance are also included. In addition, an update is provided on the basic issues and advances in molecular genetics as applied to this field. The journal will provide an important reference source for physicians and scientists who deal essentially with the clinical and laboratory diagnosis, clinical care and therapy of patients with these disorders.
-
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
被引量:- 发表:1970
-
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
被引量:- 发表:1970
-
Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.
被引量:- 发表:1970
-
Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma.
被引量:2 发表:1970
-
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
被引量:12 发表:1970